H7N9 Influenza Pseudovirus

Comprehensive Neutralization Assay Solutions for Advancing Influenza Research

Get your pseudovirus

H7N9 pseudovirus Advantages

We produce a pseudovirus pseudotyped exclusively with the hemagglutinin protein of the influenza strain A/Shanghai/4664T/2013 (H7N9) (GenBank: KC853228.1), which was responsible for the outbreak in Shanghai in 2013. These pseudoviruses carry a modified genome that expresses a luciferase or a GFP reporter gene.

Up to 1,000 reactions per mL (96-well plate)

Get a signal-to-background ratio of ≥10³ with 1 µL per well

Infectious titer of at least 10⁵ RLU/µL

The transduction efficiency is evaluated using HEK293T cells.

Lot to lot functionally validated

Infectivity and neutralization are evaluated for each batch

Lead Time: 2 - 3 week

We provide you with freshly produced pseudoviruses

QC report Order Now

Features

Enable specific detection

Expression of hemagglutinin as the sole surface antigen

Enhanced safety

Our pseudoviruses use a 3rd-generation lentivirus core and must be handled in BSL-2 conditions

Characterization of thermal stability

Stable at least 6 month at -80 °C

Support high-throughput screening

QC report Order Now

Applications

Pseudoviruses are safe and versatile tools for influenza virus research and the development of therapeutic countermeasures. Influenza pseudoviruses have several important applications in research and development, including:

Vaccine Development

They are used to test the efficacy of new vaccines by evaluating their ability to induce neutralizing immune responses without the need for live pathogenic viruses.

Neutralizing Monoclonal Antibody Screening

Pseudoviruses enable rapid and safe screening of monoclonal antibodies targeting specific strains of the influenza virus.

Antiviral Resistance Studies

They help study viral mutations and evaluate how these mutations affect sensitivity to antiviral treatments.

Fundamental Research on Viral Entry

Pseudoviruses are used to understand the mechanisms of viral entry into host cells, which is crucial for developing new therapies targeting these processes.

Treatment Efficacy Testing

They allow for the quick assessment of new antiviral agents’ effectiveness in controlled environments without the risks associated with highly pathogenic viruses.

QC report Order Now

H7N9 Influenza Virus Background

The H7N9 influenza virus is an avian subtype of the influenza A virus, known for its low pathogenicity in birds but significant virulence in humans. Like other influenza A viruses, H7N9 possesses an enveloped structure and a segmented, single-stranded negative-sense RNA genome composed of eight segments, each ranging from 890 to 2,341 nucleotides. These segments encode essential proteins involved in viral entry, replication, and assembly. The hemagglutinin (HA) of H7N9 binds to α2,3- and α2,6-linked sialic acid receptors, enabling infection of both avian and human epithelial cells. Viral entry occurs through clathrin-mediated endocytosis, followed by membrane fusion and release of viral RNA into the host nucleus. Although asymptomatic in poultry, H7N9 has caused several human outbreaks with high case-fatality rates, particularly in China. Its capacity for reassortment and silent transmission in birds highlights its pandemic potential and the urgent need for surveillance and preparedness strategies.

H7N9 Pseudovirus in Publications

The increasing number of human infections caused by avian influenza A (H7N9) viruses has intensified the need for the development of effective vaccines and antiviral strategies. The pseudovirus neutralization assay, which does not require the use of infectious viruses and can be conducted outside biosafety level 3 facilities, provides a safe and efficient platform for evaluating neutralizing monoclonal antibodies (mAbs) and antiviral compounds targeting the hemagglutinin (HA) of H7N9 viruses.

• Development of in vitro and in vivo neutralization assays based on the pseudotyped H7N9 virus
• Detection of antibodies against H5 and H7 strains in birds: evaluation of influenza pseudovirus particle neutralization tests

Order Now

Documentations

Quality Control Reports

See all reports 

SDS

Access MSDS

×

Get your document

Fill out the form below to get your document

"*" indicates required fields

Name*

First Last

Email*

This field is hidden when viewing the form

Document URL